Litcius/Paper detail

Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17–22)

Kathryn E. Stephenson, Frank Wegmann, Frank Tomaka, Stephen R. Walsh, Chen Sabrina Tan, Ludo Lavreys, Jessica L. Ansel, Diane G. Kanjilal, Kate Jaegle, Joseph P. Nkolola, Lauren Peter, Rachel Fogel, Connor Bradshaw, Anna L. Tyler, Tatenda Makoni, Lisa M. Howe, Darla Quijada, Abishek Chandrashekar, Esther A. Bondzie, Erica N. Borducchi, Katherine E. Yanosick, Jenny Hendriks, Steven Nijs, Carla Truyers, Jeroen Tolboom, Roland Zahn, Michael S. Seaman, Galit Alter, Daniel J Stieh, Maria Grazia Pau, Hanneke Schuitemaker, Dan H. Barouch

2020The Lancet HIV25 citationsDOIOpen Access PDF

Topics & Concepts

MedicineRegimenPlaceboTolerabilityHIV vaccineImmunogenicityInternal medicineVaccinationImmunologyViral loadHuman immunodeficiency virus (HIV)VirologyAdverse effectAntigenVaccine trialAlternative medicinePathologyHIV Research and TreatmentHIV/AIDS drug development and treatmentImmunotherapy and Immune Responses
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17–22) | Litcius